People

Hangil Son

Hangil Son (손한길) is published in Korea Investment Partners’ current Venture Partners directory as Executive Director. Hangil has a scientific background in cell biology and pharmacology and gained hands-on clinical development experience at Hanmi Pharmaceutical, where he worked across the scientific and clinical aspects of drug development. He moved into venture capital to take a more direct role in the commercialization of innovative technologies and has since built a portfolio spanning multiple drug modalities and aesthetic healthcare. Hangil invests across stages from early to growth, with a focus on bio and healthcare, aesthetics, and general-purpose AI platforms. His experience in pharmacology and clinical development informs his evaluation of emerging technologies, including novel mechanisms of action, longevity, and AI integration. He focuses on companies with strong scientific foundations and the potential to lead meaningful technological shifts. Published education: Ph.D., Cell Biology / Pharmacology, Yonsei University. The primary profile’s career/background list names Hanmi Pharmaceutical; undated entries are not independently verified concurrent appointments. Published areas: Bio, Healthcare, Pharma. The role is a scoped firm/regional-platform affiliation; no personal portfolio checks or separate employer at each portfolio company is inferred.